ITGAM and malignant glioma: However, SR-A1high/CD11b+ macrophages accounted for 60.8% of SR-A1+/CD11b+ macrophages in grade III gliomas but only 56.1% in grade IV gliomas, reflecting decreased SR-A1high/CD11b+ macrophages in advanced malignant glioma (Figure 1C).